FDA Outlines to Congress its Long-Awaited Approach toward LDT Regulation | GenomeWeb

This article has been updated from an earlier version with additional comments from FDA officials and industry stakeholders.

NEW YORK (GenomeWeb) – Over the next decade, the US Food and Drug Administration will phase in its risk-based approach toward regulating laboratory developed tests, the agency announced today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.